Welcome to Amorphex Therapeutics LLC


Amorphex is developing TODDD™, a soft, patented device that addresses the inaccurate and inefficient delivery, poor compliance and excessive side effects that undermine current topical ophthalmic pharmaceuticals. Topical drug delivery is critical in the treatment of many ocular diseases including glaucoma, one of the leading causes of irreversible blindness in the world.



Amorphex Therapeutics has its primary laboratory and work space at the Massachusetts Medical Device Development (M2D2) center at the University of Massachusetts- Lowell.

Copyright 2012-2016